Shares of Nuvation Bio (NUVB) are down 22c, or 9%, to 2.31 after the FDA approved Ibtrozi for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. JonesResearch stated after the approval was announced that warnings and precautions on the label are as expected for Ibtrozi, inline with the class of drugs, and better than peer drugs, such as Augtyro, Xalkori and Rozlytrek.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB: